Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in HIV-infected People Aged 1-40 Years: A Phase IV Clinical Trial
Approximately 400 HIV-infected participants aged 1-40 years old will be recruited according to the inclusion and exclusion criteria. Among them, more than 180 participants will be recruited in the immunogenicity and safety study. Each of them will receive 2 doses of HAV vaccines with a 6-month interval. Blood samples will be drawn before and 1 month after each dose to detect the HAV anitibodies to evaluate the immunogenicity of the vaccines. Other people will be recruited in the safety study and receive at least one dose of HAV vaccine. All the participants will report the adverse events within one month after each dose.
• HIV-infected participants aged 1-40 years old
• The HIV viral loads of participants in the past 12 months were supposed to be less than 200 copies/ml
• Participants or his/her guardian can fully understand and voluntarily sign the informed consent 4. Participants who are willing to participate in the 7-month follow-up 5. Participants who can provide valid legal identification